Accessibility Menu
Quantum BioPharma Ltd. logo

Quantum BioPharma Ltd.(NASDAQ) QNTM

Current Price$2.88
Market Cap$19.13MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.
Since IPO (2018)-100%
5 Year-97%
1 Year-87%
1 Month-24%
Quantum BioPharma Ltd. last closing stock price
MetricPriceDate
Last closeUSD 2.992026-07-24
Quantum BioPharma Ltd. stock price return by period
PeriodPrice returnPrice at period startPeriod start date
1 week-7.72%USD 3.242026-07-17
1 month-23.53%USD 3.912026-06-24
3 month-17.17%USD 3.612026-04-24
Year to date-59.04%USD 7.302025-12-31
1 year-87.45%USD 23.832025-07-24
3 year-95.7%USD 69.552023-07-25
5 year-97.14%USD 104.652021-07-23
Since inception-99.73%USD 1,089.632018-06-11

Quantum BioPharma Ltd. Financials at a Glance

Market Cap

$19.13MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Revenue (TTM)

$0.00

Net Income (TTM)

-$30.97M

EPS (TTM)

-$8.26

P/E Ratio

-0.36

Dividend

$0.00

Beta (Volatility)

0.94 (Low)

Price

$2.88

Volume

13,669.379

Open

$2.95

Previous Close

$2.99

Daily Range

$2.88 - $2.99

52-Week Range

$2.07 - $31.91

Estimated Earnings Date

Aug 6, 2026

QNTM News

Smoldering Fire Cannabis Bud Marijuana Weed Pot Canada US Getty

Canna-Bust! These 6 Pot Stocks Lost at Least 25% in July

Sean WilliamsAug 6, 2019
Cash Money Bills On Fire Invest Loss Bankrupt Getty

The 6 Worst Pot Stocks in the First Half of 2019

Sean WilliamsJul 2, 2019
Marijuana Plant Cannabis Pot Weed Legalization Getty

These 5 Pot Stocks Lost at Least 15% in the First Quarter

Sean WilliamsApr 9, 2019
Stock Trader Losing Money Investment Growth Value Getty

These 5 Pot Stocks Lost 16% (or More) in February

Sean WilliamsMar 5, 2019

Motley Fool Moneyball Superscore

Our CEO Is Handing Members His Secret Weapon

It's called Motley Fool Moneyball, our new proprietary AI tool

We spent over half a million dollars in R&D to build a tool that makes stock research faster, sharper, and smarter. Our analysts use it every day, and now, you can too.

Get Access Now

About Quantum BioPharma Ltd.

Quantum BioPharma Ltd. is a biopharmaceutical firm based in Toronto, Canada, focused on developing innovative solutions for complex neurodegenerative, inflammatory, and metabolic conditions. The company is advancing a diverse pipeline of drug candidates, including treatments for multiple sclerosis and alcohol use disorder.

Products and Services
  • Lucid-MS, a proprietary drug candidate in Phase 2 trials for multiple sclerosis
  • Therapeutic solutions targeting alcohol addiction for clinical environments
  • Strategic investments in collateralized loans backed by residential real estate
Growth Outlook
  • Pipeline includes promising candidates addressing significant unmet medical needs
  • Recent clinical trials show potential for Lucid-MS to reverse myelin degradation
  • Strategic investments provide additional revenue streams and financial stability
Financial Highlights
  • Recent quarterly net income of -$13.37 million reflects ongoing R&D investments
  • Cash and short-term investments total approximately $10.07 million as of Q1 2026
  • Market capitalization stands at approximately $12.75 million, indicating growth potential
Quantum BioPharma Ltd. is positioned in the biotechnology sector, focusing on innovative treatments for serious health conditions. The company’s flagship product, Lucid-MS, is currently undergoing clinical trials, with preclinical data suggesting its efficacy in addressing multiple sclerosis. Additionally, the development of a therapeutic solution for alcohol use disorder highlights the company's commitment to tackling pressing health issues. The growth outlook remains promising, with a robust pipeline and strategic investments that could enhance financial performance. Recent financial data indicates a significant investment in research and development, which is essential for long-term success in the biopharmaceutical industry. The company's cash reserves provide a buffer for ongoing operations and development activities, while its market capitalization reflects potential for future growth. Overall, Quantum BioPharma Ltd. presents an intriguing opportunity for investors interested in the biotechnology sector, particularly those focused on innovative therapeutic solutions.
AI Generated • Jul 24, 2026

Industry

Pharmaceuticals

Sector

Health Care

Employees

7

CEO

Zeeshan Saeed

Website

www.quantumbiopharma.com

Headquarters

Toronto, ON M5J 2H7, CA

QNTM Financials

Key Financial Metrics (TTM)

Gross Margin

0.00%

Operating Margin

0.00%

Net Income Margin

0.00%

Return on Equity

-621.76%

Return on Capital

-174.19%

Return on Assets

-206.82%

Earnings Yield

-2.78%

Dividend Yield

0.00%

Payout Ratio

0.00%

Stock Overview

Market Cap

$19.13MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Shares Outstanding

6.40M

Volume

13.67K

Avg. Volume

321.45K

Financials (TTM)

Gross Profit

-$125.67K

Operating Income

-$4.52M

EBITDA

-$30.93M

Operating Cash Flow

-$5.62M

Capital Expenditure

-$3.00

Free Cash Flow

-$5.62M

Cash & ST Invst.

$10.07M

Total Debt

$872.92K

Quantum BioPharma Ltd. Performance Analysis

Quantum BioPharma Ltd. annual revenue and year-over-year revenue growth by fiscal year
Fiscal yearPeriod endRevenueYoY growth
20222022-12-31USD 0N/A
20232023-12-31USD 0N/A
20242024-12-31USD 0N/A
20252025-12-31USD 0N/A
Quantum BioPharma Ltd. sequential (quarter-over-quarter) revenue growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q22025-06-30N/A
Q32025-09-30N/A
Q42025-12-31N/A
Q12026-03-31N/A
Quantum BioPharma Ltd. annual diluted earnings per share and year-over-year EPS growth by fiscal year
Fiscal yearPeriod endDiluted EPSYoY growth
20222022-12-31USD -0.61-39.6%
20232023-12-31USD -0.46-24.4%
20242024-12-31USD -12.492612.8%
20252025-12-31USD -7.97-36.2%
Quantum BioPharma Ltd. sequential (quarter-over-quarter) diluted earnings per share growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q22025-06-3059.3%
Q32025-09-3054.2%
Q42025-12-3143.6%
Q12026-03-31-277.2%

Revenue Growth Rate

Annual and quarterly growth comparison

Currently no data to display.

Earnings Per Share Growth Rate

Annual and quarterly EPS growth comparison

Quarterly Performance

Name
Q1 2026YOY CHG

Revenue

$0.00

N/A

Gross Profit

-$125.67K

N/A

Gross Margin

0.00%

N/A

Market Cap

$19.13MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

N/A

Market Cap/Employee

$1.13M

N/A

Employees

17

N/A

Net Income

-$13.37M

-55.9%

EBITDA

-$13.39M

-62.1%

Quarterly Fundamentals

Name
Q1 2026YOY CHG

Total Cash

$10.07M

+184.4%

Total Debt

$872.92K

-31.8%

Accounts Receivable

$209.21K

-93.9%

Inventory

$51.64K

-45.0%

Long Term Debt

$0.00

N/A

Short Term Debt

$872.92K

-31.8%

Return on Assets

-2.07%

N/A

Return on Invested Capital

3.17%

N/A

Free Cash Flow

-$1.65M

+61.4%

Operating Cash Flow

-$1.65M

+61.4%

Other Investments to Explore

People Also Watch

Symbol / CompanyPricePrice Chg
EVAXEvaxion Biotech A/S
$2.99+1.01%
RNTXRein Therapeutics Inc.
$0.77-3.01%
CELUCelularity Inc.
$0.77+2.07%
RMTIRockwell Medical, Inc.
$7.31+10.26%

Trending Stocks

Symbol / CompanyPricePrice Chg
NVDGraniteShares ETF Trust - GraniteShares 2x ShortDA Daily ETF
$5.24+0.10%
BMNRBitmine Immersion Technologies
$17.38+0.10%
SKHYSK Hynix
$141.20-0.09%
SKDDGraniteShares ETF Trust - GraniteShares 2x Short Sk Hynix Daily ETF
$17.52+0.18%

Questions About QNTM

What is the current price of Quantum BioPharma Ltd.?

Quantum BioPharma Ltd. is trading at $2.88 per share.

What is the 52-week range for Quantum BioPharma Ltd.?

Over the past 52 weeks, Quantum BioPharma Ltd. has traded between $2.07 and $31.91.

How much debt does Quantum BioPharma Ltd. have?

As of the most recent reporting period, Quantum BioPharma Ltd. reported total debt of $870.06K.

How much cash does Quantum BioPharma Ltd. have on hand?

Quantum BioPharma Ltd. reported $4.34M in cash and cash equivalents in its most recent financial results.

What is Quantum BioPharma Ltd.’s dividend yield?

Quantum BioPharma Ltd. does not currently have a dividend yield.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.

View Premium Services